The Real Value of Firefinch, page-3

The company really hasn’t done the job on Goulamina, the scoping study is subject to review according to DEC Quarterly, and the confirmatory testwork should be done as a part of FFX now.

5 months have passed since the DFS, there’s nothing to stop doing testwork on the intermediary or final endpoint lithia derivative to make most of the asset to negotiate with?